All In Biotech

Drug Trial Radar · NCT04219007

Vosoritide for Selected Genetic Causes of Short Stature

Last checked: Nov 20, 2026Latest source record: Mar 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

56

Actual

Start

Aug 4, 2020

Primary completion

Aug 14, 2025

Study completion Jun 1, 2035

Sponsor

Lead sponsor
Andrew DauberAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 6, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 10 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Short stature can be caused by a number of genetic etiologies, many of which directly affect the growth plate. The FGFR3/CNP pathway is central to growth of the chondrocyte. The study team hypothesizes that patients with selected genetic causes of short stature that interact with this pathway will benefit from treatment with vosoritide, a CNP analog, a selective NPR-B agonist which directly targets the growth plate. This study will enroll patients with short stature in selected genetic categories and will follow them for a 6 month observation period to obtain a baseline growth velocity, safety profile and quality of life assessment. Patients will then be treated with vosoritide for 12 months and will be assessed for safety monitoring and improvement in height outcomes.

Conditions

  • Short Stature

Interventions

  • VosoritideDrug

    After enrollment, subjects will be followed for a 6 month observation only period to establish a baseline height velocity as well as safety profile and quality of life assessment. Vosoritide will then be administered daily via subcutaneous injection at a dose of 15 µg/kg/day for 12 months.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]Time frame: 12 months
  2. Incidence of Symptomatic Hypotension events [Safety and Tolerability]Time frame: 12 months
  3. Change from Baseline in annualized growth velocityTime frame: 12 months
  4. Change from Baseline in standardized height SDSTime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Children's National Hospital

    Washington D.C., District of Columbia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.